PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical modelsKeith Dredge, Ian Bytheway, Maree T. Smith et al.|British Journal of Cancer|2011Cited by 165
Abstract A17: The dual angiogenesis/heparanase inhibitor PG545 inhibits solid tumor progression in models of breast, prostate and liver cancer: A comparative assessment of once versus twice weekly administration schedulesEdward Hammond, Keith Dredge, Ian Bytheway et al.|Molecular Cancer Therapeutics|2009Cited by 3